ClinicalTrials.gg
RecruitingNCT06781281Updated Jun 23, 2025

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

An observational study in Breast Cancer Invasive, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-23.

Sponsored by Henan Cancer Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
709
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Breast Neoplasms by Henan Cancer Hospital — 29 open to participants now, 32 under way, 3 of them phase 3. Breast Neoplasms · Henan Cancer Hospital.

Started
2024
with 6 others
Observational
5 of 45
4 open now
Primary completion
2026-11
later than 11 of 31 live
Registered
30th of 45
by date

Among the 45 studies in Breast Neoplasms by Henan Cancer Hospital, this one is one of 7 that started in 2024, is one of 5 observational ones, reaches primary completion later than 11 of the 31 other live ones, and was the 30th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

29 of the 45 studies in Breast Neoplasms by Henan Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Breast Neoplasms by Henan Cancer Hospital, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn if serplulimab is effective in early HR+/HER2- breast cancer. This trial serves a prospective parallel control cohort for HELEN-018 (NCT). The main questions it aims to answer are:

Does serplulimab combined with neoadjuvant chemotherapy improve the pCR rate of early HR+/HER2- breast cancer? What medical problems do participants have when receiving serplulimab? Researchers will compare the effect of serplulimab combined with chemotherapy to the effect of chemotherapy reported in literature.

Participants will: Receive serplulimab plus chemotherapy every 3 weeks for 6 cycles; All patients will receive surgery, and the primary end point is a pathological complete response at the time of definitive surgery; After definitive surgery, the participants will receive adjuvant serplulimab every 3 weeks for up to 6 months from the begining of the treatment.

Read the detailed description

In recent years, significant progress has been made in the immunotherapy of breast cancer, and PD1/PDL1 inhibitors have achieved good results in the treatment of triple-negative breast cancer. There have also been many attempts to apply them in HR+/HER2- breast cancer. In the I-SPY2 study, Pembrolizumab combined with chemotherapy increased the pCR rate of HR+/HER2- breast cancer from 13% in the chemotherapy alone group to 30%. In the KEYNOTE756 study, Pembrolizumab in combination with chemotherapy increased the pCR rate by 8.5% (24.3% vs. 15.6%) compared to the chemotherapy-only arm in HR+/HER2- breast cancer. pCR rates in the nivolizumab arm of the CheckMate 7FL study were 24.5% compared with 13.8% in the control arm. While further long-term follow-up data are still needed to confirm patient benefit, it still provides a new treatment option for HR+/HER2- breast cancer patients.

The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens. Several clinical studies have confirmed that albumin paclitaxel is more effective than solvent-based paclitaxel, and therefore, albumin paclitaxel in combination with epirubicin has also become a commonly used chemotherapy regimen in clinical practice.

The aim of this study was to explore the efficacy and safety of the Serplulimab combined with nab-paclitaxel and epirubicin in the neoadjuvant treatment of HR+/HER2- breast cancer

03

Conditions studied

  • Breast Cancer Invasive

Browse trials for

Keywords

  • HR+/HER2-
  • PD1
  • Real-world study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All female breast cancer patients diagnosed and scheduled to receive neoadjuvant chemotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age>=18 years old
  2. cT2 - cT4d, or cT1c with axillary lymph node confirmed clinically and pathologically;
  3. proven HR+/- breast cancer:

    defined as:

    • positive for ER or PR (IHC nuclear staining >1%)
    • Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with no amplification by FISH);
  4. Has clinically :Measurable lesions on ultrasound, mammography, or MR (optional) within 1 month before randomization;
  5. Organ and bone marrow function tests within 1 month before chemotherapy suggest no to chemotherapy;
  6. Cardiac ultrasound EF value ≧55%;
  7. Females of childbearing age, with a negative serum pregnancy test 14 days before randomization;
  8. score≤1 point;
  9. Sign ;

Exclusion criteria

Exclusion Criteria:

  1. The patient has evidence of breast cancer;
  2. For this disease, chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. have been received;
  3. The patient has a second primary other than adequately treated skin cancer;
  4. The patient has been treated with anti-programmed cell death protein 1 (), anti-programmed death ligand 1 (anti-PD-L1) or anti-PD-L2 drugs, or other immunotherapy;
  5. The patient has been diagnosed with immunodeficiency disease or disease;
  6. The patient has severe lung or heart disease;
  7. The patient has active and C;
  8. The patient has a history of organ transplantation or bone marrow transplantation;
  9. pregnant or breastfeeding women;
  10. The investigators considered chemotherapy due to serious, uncontrolled other medical conditions.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
709 participants (estimated)
Patient registry
No

Groups and cohorts

  • NabPE+Serplulimab group

    Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serplulimab 4.5mg/Kg ivgtt on Day 3, every 3 weeks for 6 cycles.

    Drug: Serplulimab · Drug: NabPE

  • NabPE

    Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1, every 3 weeks for 6 cycles.

    Drug: NabPE

Interventions

  • Serplulimab

  • DrugNabPE

    Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2

06

What researchers measure

Primary outcomes

  1. pathological complete response

    After neoadjuvant chemotherapy and surgery, the resected specimen (breast + axilla) was free of any invasive cancer (ie, ypT0/is, ypN0)

    Time frame: 24 weeks

Secondary outcomes

  1. Event-Free Survival (EFS)

    EFS was defined as the time from randomization to any of the following events: disease progression during neoadjuvant therapy, local or distant recurrence, second primary malignancy (breast or other cancer), or death from any cause.

    Time frame: 5-10 years

  2. DFS

    Disease-free Survival,From the date of surgery to the first local, regional, contralateral or distant recurrence, and death from any cause

    Time frame: 5-10 years

  3. Objective Response Rate (ORR)

    ORR is defined as the number of target lesion responders as assessed by MRI

    Time frame: 24 WEEKS

  4. adverse events

    Evaluate the nature, incidence and severity of chemotherapy adverse events according to CTCAE 5.0

    Time frame: After each cycle of chemotherapy (21 days as 1 cycle)]

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 23 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Jan 17, 2025
StartActual
Dec 4, 2024
Primary completionEst.
Nov 28, 2026
CompletionEst.
Nov 28, 2030
Last update
Jun 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06781281
Responsible party
Zhenzhen Liu (Professor, Henan Cancer Hospital) — Principal investigator
First posted
Jan 17, 2025
Start date
Dec 4, 2024
Primary completion
Nov 28, 2026 (estimated)
Completion
Nov 28, 2030 (estimated)
Last update
Jun 23, 2025

Study contacts

Zhenzhen Liu, Dr.
Contact
zlyyliuzhenzhen0800@zzu.edu.cn
13603862755

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion